StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT – Free Report) in a research note issued to investors on Saturday morning. The brokerage issued a hold rating on the stock.

Healthcare proved to be a resilient market for mergers and acquisitions in 2024, despite deal volume declining 9% from 2023. ...

2024 was quite a year for significant strategic action among the pharmaceutical giants. Here are five key trends that will ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This Semaglutides market report covers market characteristics, size and growth, segmentation, regional ...

M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation (CDMO) Catalent does not create competition issues and can go ahead, according to the European ...

A large pharmaceutical company collaborated with DelveInsight to evaluate CDMO companies for API and FD development. DelveInsight provided a comprehensive one-time report benchmarking top contract ...

Pharmaceutical Cartridges Market Driven by rising demand for self-administered therapies & advanced drug delivery systems, the <a target ...